| Name | Title | Contact Details |
|---|
Lancaster County Motors is an automotive sales and service company based in East Petersburg, Pennsylvania. Our dealerships include Lancaster County Motors Subaru, Lancaster Hyundai, Lancaster County Kia, Mercedes-Benz of Lancaster, Providence Autos, and LCM Used Cars.
Lockton Affinity is a division of Lockton Companies that focuses on underwriting and distributing specialty insurance products. It operates in markets that are outside the standard offerings, catering to unique insurance needs. Lockton Companies, the parent organization, is a global insurance brokerage known for its client-focused and family-owned approach.
DRAXXON is a global manufacturer of specialty vehicle solutions, integrating cutting edge technology into vans, SUVS, trailers, and ruggedized Pelican case configurations.
Honest1, a national full-service auto care company, is passionate about putting customers first. Its customer-centric, transparent approach assures every customer is thoroughly educated on the systems and services necessary to keep their vehicles in the best running condition. Honest1 centers are family-friendly with clean and upscale waiting areas, Internet cafes, childrens play areas, comfortable leather chairs and couches, HDTVs and complimentary beverage stations. In addition to putting its customers first, Honest1 Auto Care performs H-1 ESA Quality checks at each of its locations to ensure performance is environmentally sustainable.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.